Navigation Links
Treatment May Limit Graft-Versus-Host Disease
Date:8/19/2009

Problem in stem-cell transplants is common when donor, recipient are not related

WEDNESDAY, Aug. 19 (HealthDay News) -- People who need a blood stem-cell transplant may be able to lessen the chances that the transplanted material will attack the body -- what's known as graft-versus-host disease -- by being treated with anti-T-cell globulin, a new study has shown.

Graft-versus-host disease (GVHD) occurs in up to 60 percent of those who have a transplant of blood stem cells -- called hematopoietic cell transplantation -- from the bone marrow or peripheral blood of unrelated donors. In GVHD, the immune system or T-cells from the donor recognize the recipient's tissues as foreign and attack. Previous research has suggested that antibodies that eliminate T-cells might prevent this attack.

The new study included 201 adults with blood cancer who were scheduled for a transplant from an unrelated donor. One group was given standard treatment to prevent GVHD prophylaxis (cyclosporine and methotrexate), and the others were given the standard therapy plus anti-T-cell globulin (anti-Jurkat ATG-Fresenius, or ATG-F).

Within 100 days, about 34 percent (33 people) in the standard treatment group had developed acute GVHD or had died, compared with 21 percent (22 people) of those in the ATG-F group. The difference during the first 100 days was not considered statistically significant, the researchers noted.

However, the study found that the overall incidence of acute GVHD was less in the ATG-F group (12 percent) than among those who'd gotten just the standard treatment (24 percent). One person given ATG-F died, compared with nine who had not gotten ATG-F.

The phase 3 trial also found that the two-year cumulative incidence of chronic GVHD and extensive chronic GVHD in the ATG-F group was about 31 percent and 12 percent, respectively, compared with 59 percent and 43 percent for the standard treatment group.

The ATG-F group did not have higher rates than the standard treatment group for relapse, deaths not related to relapse or deaths from infection, the study authors found.

"This is the first randomized clinical trial to show that ATG-F can reduce severe acute and clinically relevant chronic GVHD without compromising disease-free survival or overall survival," Dr. Jurgen Finke, of Universitatsklinikum Freiburg in Germany, and fellow researchers said in a news release from The Lancet Oncology, which is publishing the study online Aug. 19 and in its September print issue.

"The use of ATG-F is safe for patients who are going to receive transplantation from matched unrelated donors," they said.

More information

The U.S. National Library of Medicine has more on graft-versus-host disease.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, Aug. 18, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Argonne, University of Chicago scientists develop targeted cancer treatment using nanomaterials
2. Study finds adverse effects in treatment for primary sclerosing cholangitis
3. Milk is safe, even encouraged, for some children after treatment for milk allergy
4. Estrogen Plays Surprise Role in Breast Cancer Treatment
5. Mylans Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
6. Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes
7. Post-treatment pain in head and neck cancer patients linked to recurrence, lower survival rate
8. Mothers Immune System May Block Fetal Treatments for Blood Diseases
9. Genetic Discovery May Improve Hepatitis C Treatment
10. New biomarker predicts response to hepatitis C treatment
11. Cooling treatment after cardiac arrest is cost-effective, Penn study shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Treatment May Limit Graft-Versus-Host Disease
(Date:10/13/2017)... ... 13, 2017 , ... Ellevate Network, the leading network for professional women, brought ... gender equality at their inaugural Summit in New York City in June. The event ... audience of over 3 million. To watch the Mobilize Women video, click here ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
(Date:10/4/2017)... WESTWOOD, Mass. , Oct. 4, 2017  According to the Centers ... by the end of October . PhysicianOne Urgent Care is helping communities ... Westchester, NY , by offering no-cost* flu shots through ... , as mandated by certain health insurance regulations. ... The best time to get a flu shot is by ...
(Date:10/2/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: ... Consulting, LLC , and named its founder as Diplomat,s ... Tennessee , will operate under Diplomat ... service offerings for health care partners to include IT ... "In an interoperable world, technology delivers comprehensive ...
Breaking Medicine Technology: